NeoGenomics (NEO) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

NEO Stock Forecast

NeoGenomics stock forecast is as follows: an average price target of $19.00 (represents a 15.85% upside from NEO’s last price of $16.40) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.

NEO Price Target

The average price target for NeoGenomics (NEO) is $19.00 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $19.00 to $19.00. This represents a potential 15.85% upside from NEO's last price of $16.40.

NEO Analyst Ratings

Buy

According to 9 Wall Street analysts, NeoGenomics's rating consensus is 'Buy'. The analyst rating breakdown for NEO stock is 0 'Strong Buy' (0.00%), 8 'Buy' (88.89%), 1 'Hold' (11.11%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

NeoGenomics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jul 30, 2024	Mike Matson	Needham	$19.00	$14.64	29.78%	15.85%
May 02, 2024	Mark Massaro	BTIG	$21.00	$13.96	50.43%	28.05%
Aug 21, 2023	Mason Carrico	Stephens	$18.00	$14.08	27.84%	9.76%
Aug 17, 2022	David Westenberg	Piper Sandler	$19.00	$11.64	63.23%	15.85%
Aug 10, 2022		Morgan Stanley	$18.00	$11.66	54.37%	9.76%
Aug 10, 2022		Goldman Sachs	$20.00	$11.59	72.56%	21.95%
Aug 10, 2022		Needham	$16.00	$11.68	36.99%	-2.44%
Apr 28, 2022		Raymond James	$15.00	$10.44	43.68%	-8.54%
Jun 03, 2021	Matthew Sykes	Goldman Sachs	$55.00	$40.11	37.12%	235.37%
May 25, 2021	Sandy Draper	Guggenheim	$54.00	$39.17	37.86%	229.27%

The latest NeoGenomics stock forecast, released on Jul 30, 2024 by Mike Matson from Needham, set a price target of $19.00, which represents a 29.78% increase from the stock price at the time of the forecast ($14.64), and a 15.85% increase from NEO last price ($16.40).

NeoGenomics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$20.00
Last Closing Price	$16.40	$16.40	$16.40
Upside/Downside	-100.00%	-100.00%	21.95%

In the current month, the average price target of NeoGenomics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to NeoGenomics's last price of $16.40. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 24, 2024	Stephens	Buy	Buy	Hold
Sep 24, 2024	Benchmark	Buy	Buy	Hold
Jul 30, 2024	Needham	Buy	Buy	Hold
May 02, 2024	BTIG	Buy	Buy	Hold
Mar 18, 2024	Piper Sandler	Buy	Buy	Hold
Feb 22, 2024	Goldman Sachs	Buy	Buy	Hold
Feb 21, 2024	Needham	Buy	Buy	Hold
Feb 21, 2024	Cowen & Co.	Underperform	Underperform	Hold
Dec 29, 2023	Cowen & Co.	Outperform	Outperform	Hold
Dec 28, 2023	Piper Sandler	Buy	Buy	Hold
Aug 21, 2023	Stephens		Overweight	Upgrade
May 09, 2023	BTIG		Buy	Upgrade
Feb 24, 2023	Cowen & Co.	Outperform	Outperform	Hold
Feb 23, 2023	William Blair	Outperform	Outperform	Hold
Feb 01, 2023	Needham	Hold	Buy	Upgrade
Aug 22, 2022	Needham	Buy	Hold	Downgrade
Aug 17, 2022	Piper Sandler	Overweight	Overweight	Hold
Aug 10, 2022	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
Aug 10, 2022	Goldman Sachs	Buy	Buy	Hold
Aug 10, 2022	Needham	Buy	Buy	Hold
Apr 28, 2022	Raymond James	Outperform	Outperform	Hold
Feb 24, 2022	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
Feb 24, 2022	Needham	Buy	Buy	Hold
Feb 24, 2022	Raymond James	Outperform	Outperform	Hold

NeoGenomics's last stock rating was published by Stephens on Sep 24, 2024. The company gave NEO a "Buy" rating, the same as its previous rate.

NeoGenomics Financial Forecast

NeoGenomics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$151.95M	$146.92M	$137.22M	$138.71M	$128.78M	$125.07M	$117.17M	$125.73M	$121.34M	$121.72M	$115.53M	$126.00M	$125.44M	$86.98M	$106.03M	$106.87M	$104.67M
Avg Forecast	$206.92M	$202.14M	$197.57M	$187.27M	$190.06M	$184.48M	$180.81M	$171.98M	$173.05M	$167.00M	$161.82M	$149.85M	$152.54M	$141.67M	$137.45M	$129.27M	$129.97M	$121.54M	$122.93M	$116.71M	$125.74M	$124.56M	$121.47M	$112.14M	$123.65M	$126.22M	$86.55M	$105.24M	$104.25M	$99.38M
High Forecast	$209.95M	$205.10M	$200.46M	$190.01M	$192.84M	$187.18M	$183.46M	$173.79M	$175.74M	$167.01M	$161.82M	$149.85M	$155.35M	$145.93M	$139.46M	$131.16M	$131.87M	$121.54M	$122.93M	$116.71M	$125.74M	$124.56M	$121.47M	$112.14M	$123.65M	$126.22M	$86.55M	$105.24M	$104.25M	$99.38M
Low Forecast	$203.38M	$198.68M	$194.19M	$184.06M	$186.80M	$181.32M	$177.72M	$169.96M	$170.72M	$167.00M	$161.82M	$149.85M	$148.65M	$138.18M	$135.10M	$127.06M	$127.74M	$121.54M	$122.93M	$116.71M	$125.74M	$124.56M	$121.47M	$112.14M	$123.65M	$126.22M	$86.55M	$105.24M	$104.25M	$99.38M
# Analysts	5	4	5	4	4	3	4	8	10	9	3	3	6	11	5	9	5	4	4	7	5	5	10	7	5	10	10	10	9	9
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.07%	1.07%	1.06%	1.07%	1.06%	1.02%	1.00%	1.00%	0.97%	1.00%	1.03%	1.02%	0.99%	1.00%	1.01%	1.03%	1.05%

NeoGenomics's average Quarter revenue forecast for Dec 23 based on 6 analysts is $152.54M, with a low forecast of $148.65M, and a high forecast of $155.35M. NEO's average Quarter revenue forecast represents a 0.39% increase compared to the company's last Quarter revenue of $151.95M (Sep 23).

NeoGenomics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	5	4	5	4	4	3	4	8	10	9	3	3	6	11	5	9	5	4	4	7	5	5	10	7	5	10	10	10	9	9
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-24.20M	$-29.89M	$-7.87M	$-23.31M	$-22.02M	$-22.69M	$-35.14M	$-25.64M	$-5.22M	$85.04M	$-10.82M	$19.39M	$13.68M	$-3.10M	$3.62M	$10.40M	$10.92M
Avg Forecast	$4.46M	$4.36M	$4.26M	$4.04M	$4.10M	$3.98M	$3.90M	$3.71M	$3.73M	$3.60M	$3.49M	$-51.40M	$3.29M	$3.05M	$2.96M	$-46.73M	$-28.20M	$2.04M	$2.07M	$-42.48M	$2.11M	$2.09M	$2.04M	$-58.44M	$2.08M	$2.12M	$1.45M	$9.78M	$1.75M	$1.67M
High Forecast	$4.52M	$4.42M	$4.32M	$4.09M	$4.16M	$4.03M	$3.95M	$3.74M	$3.79M	$3.60M	$3.49M	$-41.12M	$3.35M	$3.14M	$3.01M	$-37.38M	$-22.56M	$2.04M	$2.07M	$-33.98M	$2.11M	$2.09M	$2.04M	$-46.76M	$2.08M	$2.12M	$1.45M	$11.74M	$1.75M	$1.67M
Low Forecast	$4.38M	$4.28M	$4.18M	$3.97M	$4.03M	$3.91M	$3.83M	$3.66M	$3.68M	$3.60M	$3.49M	$-61.68M	$3.20M	$2.98M	$2.91M	$-56.07M	$-33.84M	$2.04M	$2.07M	$-50.97M	$2.11M	$2.09M	$2.04M	$-70.13M	$2.08M	$2.12M	$1.45M	$7.82M	$1.75M	$1.67M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-7.93%	-10.09%	0.17%	0.83%	-10.78%	-10.98%	0.83%	-12.13%	-2.49%	41.66%	0.19%	9.33%	6.45%	-2.13%	0.37%	5.94%	6.54%

5 analysts predict NEO's average Quarter EBITDA for Sep 21 to be $2.09M, with a high of $2.09M and a low of $2.09M. This is -97.54% lower than NeoGenomics's previous annual EBITDA (Jun 21) of $85.04M.

NeoGenomics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	5	4	5	4	4	3	4	8	10	9	3	3	6	11	5	9	5	4	4	7	5	5	10	7	5	10	10	10	9	9
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-18.52M	$-24.33M	$-30.80M	$-22.69M	$-36.85M	$-35.30M	$-49.41M	$-41.76M	$-20.35M	$75.87M	$-22.11M	$15.42M	$2.56M	$-6.82M	$-6.98M	$6.30M	$2.14M
Avg Forecast	$12.64M	$11.53M	$11.08M	$6.69M	$8.51M	$6.95M	$6.80M	$3.14M	$3.57M	$1.56M	$-393.55K	$-67.58M	$-3.14M	$-9.47M	$-14.49M	$-61.44M	$-45.93M	$-26.06M	$-29.65M	$-55.85M	$-19.08M	$-11.38M	$-1.69M	$-119.42M	$7.55M	$4.80M	$-13.11M	$-18.84M	$8.13M	$7.58M
High Forecast	$12.89M	$11.75M	$11.29M	$6.82M	$8.67M	$7.08M	$6.93M	$5.24M	$7.13M	$1.58M	$-384.79K	$-54.07M	$-3.07M	$-5.92M	$-14.16M	$-49.15M	$-36.75M	$-26.06M	$-29.65M	$-44.68M	$-19.08M	$-11.38M	$-1.69M	$-95.53M	$7.55M	$4.80M	$-13.11M	$-15.07M	$8.13M	$7.58M
Low Forecast	$12.36M	$11.27M	$10.84M	$6.54M	$8.32M	$6.79M	$6.65M	$1.05M	$1.78M	$1.54M	$-401.04K	$-81.10M	$-3.20M	$-18.95M	$-14.76M	$-73.73M	$-55.12M	$-26.06M	$-29.65M	$-67.02M	$-19.08M	$-11.38M	$-1.69M	$-143.30M	$7.55M	$4.80M	$-13.11M	$-22.61M	$8.13M	$7.58M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.95%	1.68%	0.50%	0.49%	1.41%	1.19%	0.88%	2.19%	1.79%	-45.02%	0.19%	2.04%	0.53%	0.52%	0.37%	0.77%	0.28%

NeoGenomics's average Quarter net income forecast for Sep 21 is $-11.38M, with a range of $-11.38M to $-11.38M. NEO's average Quarter net income forecast represents a -114.99% decrease compared to the company's last Quarter net income of $75.87M (Jun 21).

NeoGenomics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	5	4	5	4	4	3	4	8	10	9	3	3	6	11	5	9	5	4	4	7	5	5	10	7	5	10	10	10	9	9
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$79.10M	$79.21M	$77.81M	$75.00M	$81.09M	$75.02M	$82.55M	$78.31M	$79.54M	$71.86M	$54.23M	$49.81M	$47.43M	$44.81M	$49.60M	$45.52M	$44.56M
Avg Forecast	$107.04M	$104.57M	$102.20M	$96.87M	$98.32M	$95.43M	$93.53M	$88.96M	$89.52M	$86.39M	$83.71M	$112.91M	$78.91M	$73.29M	$71.10M	$102.65M	$86.14M	$62.87M	$63.59M	$93.31M	$65.05M	$64.44M	$62.83M	$58.01M	$63.96M	$65.30M	$44.77M	$54.44M	$53.93M	$51.41M
High Forecast	$108.61M	$106.10M	$103.70M	$98.29M	$99.75M	$96.83M	$94.90M	$89.90M	$90.91M	$86.39M	$83.71M	$135.49M	$80.36M	$75.49M	$72.14M	$123.17M	$103.37M	$62.87M	$63.59M	$111.98M	$65.05M	$64.44M	$62.83M	$58.01M	$63.96M	$65.30M	$44.77M	$54.44M	$53.93M	$51.41M
Low Forecast	$105.21M	$102.78M	$100.45M	$95.21M	$96.63M	$93.80M	$91.93M	$87.92M	$88.31M	$86.39M	$83.71M	$90.33M	$76.90M	$71.48M	$69.88M	$82.12M	$68.91M	$62.87M	$63.59M	$74.65M	$65.05M	$64.44M	$62.83M	$58.01M	$63.96M	$65.30M	$44.77M	$54.44M	$53.93M	$51.41M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.08%	1.11%	0.76%	0.87%	1.29%	1.18%	0.88%	1.20%	1.23%	1.14%	0.93%	0.78%	0.73%	1.00%	0.91%	0.84%	0.87%

NeoGenomics's average Quarter SG&A projection for Dec 23 is $78.91M, based on 6 Wall Street analysts, with a range of $76.90M to $80.36M. The forecast indicates a -0.23% fall compared to NEO last annual SG&A of $79.10M (Sep 23).

NeoGenomics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	5	4	5	4	4	3	4	8	10	9	3	3	6	11	5	9	5	4	4	7	5	5	10	7	5	10	10	10	9	9
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.15	$-0.19	$-0.25	$-0.18	$-0.30	$-0.28	$-0.40	$-0.34	$-0.17	$0.64	$-0.19	$0.14	$0.02	$-0.06	$-0.07	$0.06	$0.02
Avg Forecast	$0.10	$0.09	$0.09	$0.05	$0.07	$0.05	$0.05	$0.02	$0.03	$0.01	$-0.00	$-0.04	$-0.02	$-0.07	$-0.11	$-0.14	$-0.16	$-0.21	$-0.23	$-0.24	$-0.15	$-0.09	$-0.01	$0.01	$0.06	$0.04	$-0.10	$0.02	$0.06	$0.06
High Forecast	$0.10	$0.09	$0.09	$0.05	$0.07	$0.06	$0.05	$0.04	$0.06	$0.01	$-0.00	$-0.04	$-0.02	$-0.05	$-0.11	$-0.14	$-0.16	$-0.21	$-0.23	$-0.24	$-0.15	$-0.09	$-0.01	$0.01	$0.06	$0.04	$-0.10	$0.02	$0.06	$0.06
Low Forecast	$0.10	$0.09	$0.09	$0.05	$0.07	$0.05	$0.05	$0.01	$0.01	$0.01	$-0.00	$-0.04	$-0.03	$-0.15	$-0.12	$-0.14	$-0.17	$-0.21	$-0.23	$-0.24	$-0.15	$-0.09	$-0.01	$0.01	$0.06	$0.04	$-0.10	$0.02	$0.06	$0.06
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	2.01%	1.67%	1.79%	1.09%	1.46%	1.19%	1.68%	2.25%	1.89%	-48.00%	-21.26%	2.34%	0.53%	0.61%	-3.56%	0.93%	0.33%

According to 5 Wall Street analysts, NeoGenomics's projected average Quarter EPS for Sep 21 is $-0.09, with a low estimate of $-0.09 and a high estimate of $-0.09. This represents a -114.06% decrease compared to NEO previous annual EPS of $0.64 (Jun 21).

NeoGenomics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
MYGN	Myriad Genetics	$13.82	$30.20	118.52%	Hold
BDSX	Biodesix	$1.39	$3.00	115.83%	Buy
ACRS	Aclaris Therapeutics	$3.26	$6.00	84.05%	Buy
CDNA	CareDx	$22.14	$37.50	69.38%	Buy
ICLR	ICON Public Limited Company	$203.26	$337.00	65.80%	Buy
NEOG	Neogen	$12.13	$17.50	44.27%	Buy
CSTL	Castle Biosciences	$28.14	$40.50	43.92%	Buy
IQV	IQVIA	$196.64	$252.80	28.56%	Buy
SHC	Sotera Health Company	$13.08	$16.00	22.32%	Buy
GH	Guardant Health	$34.84	$40.60	16.53%	Buy
MTD	Mettler-Toledo	$1.25K	$1.41K	13.28%	Hold
CRL	Charles River Laboratories	$189.33	$209.00	10.39%	Buy
NEO	NeoGenomics	$17.55	$19.00	8.26%	Buy
QGEN	Qiagen	$45.34	$48.33	6.59%	Buy
TWST	Twist Bioscience	$48.40	$46.00	-4.96%	Buy
NTRA	Natera	$168.21	$151.50	-9.93%	Buy

NEO Forecast FAQ

Is NeoGenomics a good buy?

Yes, according to 9 Wall Street analysts, NeoGenomics (NEO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 88.89% of NEO's total ratings.

What is NEO's price target?

NeoGenomics (NEO) average price target is $19 with a range of $19 to $19, implying a 15.85% from its last price of $16.4. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will NeoGenomics stock go up soon?

According to Wall Street analysts' prediction for NEO stock, the company can go up by 15.85% (from the last price of $16.4 to the average price target of $19), up by 15.85% based on the highest stock price target, and up by 15.85% based on the lowest stock price target.

Can NeoGenomics stock reach $20?

NEO's average twelve months analyst stock price target of $19 does not support the claim that NeoGenomics can reach $20 in the near future.

What are NeoGenomics's analysts' financial forecasts?

NeoGenomics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $727.32M (high $737.27M, low $715.79M), average EBITDA is $15.67M (high $15.89M, low $15.42M), average net income is $25.4M (high $27.92M, low $22.81M), average SG&A $376.24M (high $381.39M, low $370.28M), and average EPS is $0.2 (high $0.22, low $0.18). NEO's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $793.9M (high $805.52M, low $780.3M), average EBITDA is $17.11M (high $17.36M, low $16.81M), average net income is $41.94M (high $42.74M, low $41.01M), average SG&A $410.68M (high $416.7M, low $403.65M), and average EPS is $0.33 (high $0.337, low $0.323).

Did the NEO's actual financial results beat the analysts' financial forecasts?

Based on NeoGenomics's last annual report (Dec 2022), the company's revenue was $509.73M, beating the average analysts forecast of $491.15M by 3.78%. Apple's EBITDA was $-83.89M, beating the average prediction of $-66.568M by 26.02%. The company's net income was $-144M, missing the average estimation of $-157M by -8.41%. Apple's SG&A was $310.68M, beating the average forecast of $305.92M by 1.56%. Lastly, the company's EPS was $-1.16, beating the average prediction of $-0.843 by 37.61%. In terms of the last quarterly report (Sep 2023), NeoGenomics's revenue was $151.95M, beating the average analysts' forecast of $141.67M by 7.26%. The company's EBITDA was $-24.195M, missing the average prediction of $3.05M by -892.56%. NeoGenomics's net income was $-18.516M, beating the average estimation of $-9.474M by 95.45%. The company's SG&A was $79.1M, beating the average forecast of $73.29M by 7.93%. Lastly, the company's EPS was $-0.15, beating the average prediction of $-0.0746 by 101.01%